Adage Capital Partners Gp, L.L.C. Cardiff Oncology, Inc. Call Options Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
126Shares Held
26.4MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.73MShares$8.61 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.07 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.83 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$4.15 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.46 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $100M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...